Antibody-drug conjugates in breast cancer: Marching from HER2-overexpression into HER2-low

被引：9

作者：

Fan, Pinchao ^{[1
]}

Xu, Kun ^{[2
,3
,4
]}

机构：

[1] Nanjing Med Univ, Clin Med Coll 1, Nanjing 211166, Peoples R China

[2] Nanjing Med Univ, Jiangsu Canc Hosp, Dept Oncol, 42 Baiziting, Nanjing 210009, Peoples R China

[3] Nanjing Med Univ, Jiangsu Inst Canc Res, 42 Baiziting, Nanjing 210009, Peoples R China

[4] Nanjing Med Univ, Affiliated Canc Hosp, 42 Baiziting, Nanjing 210009, Peoples R China

来源：

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER | 2023年 / 1878卷 / 01期

关键词：

Antibody-drug conjugate; Breast cancer; HER2-overexpression; HER2-low; TRASTUZUMAB EMTANSINE T-DM1; SACITUZUMAB GOVITECAN; SINGLE-ARM; CHEMOTHERAPY; EXPRESSION; METASTASES; THERAPY; DISEASE; COHORT; TUMORS;

D O I：

10.1016/j.bbcan.2022.188849

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The recent decade has witnessed a vigorous prosper of antibody-drug conjugates (ADCs) in solid tumors including breast cancer. Integrating the specificity of monoclonal antibodies and potency of cytotoxic drugs, ADCs are capable of delivering cytotoxic agents directly to tumor cells and surrounding accomplices with het-erogeneous antigen expression by exerting the distinctive bystander effect. Up till now, three ADCs (T-DM1, T-DXd and SG) have attained the official approval and stepped into clinical practices in breast cancer, with numerous promising products in the pipeline. As an unprecedented breast cancer subgroup identified following solidified drug benefit, the cognitive and therapeutic paradigm of HER2-low population which was previously thought lacking definite targets and efficacious regimens has been thoroughly rewritten by ADCs, and several encouraging achievements are expected in ongoing trials. Herein, we discuss the contrived knowledge, latest advancements and future perspectives of ADCs in HER2-overexpressing and HER2-low breast cancer.

引用

页数：12

共 99 条

[11] Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial [J].

Bartsch, Rupert ;

Berghoff, Anna Sophie ;

Furtner, Julia ;

Marhold, Maximilian ;

Bergen, Elisabeth Sophie ;

Roider-Schur, Sophie ;

Starzer, Angelika Martina ;

Forstner, Heidrun ;

Rottenmanner, Beate ;

Dieckmann, Karin ;

Bago-Horvath, Zsuzsanna ;

Haslacher, Helmuth ;

Widhalm, Georg ;

Ilhan-Mutlu, Aysegul ;

Minichsdorfer, Christoph ;

Fuereder, Thorsten ;

Szekeres, Thomas ;

Oehler, Leopold ;

Gruenberger, Birgit ;

Singer, Christian F. ;

Weltermann, Ansgar ;

Puhr, Rainer ;

Preusser, Matthias .

NATURE MEDICINE, 2022, 28 (09) :1840-+

[12] Monoclonal antibody therapeutics: history and future [J].

Buss, Nicholas A. P. S. ;

Henderson, Simon J. ;

McFarlane, Mary ;

Shenton, Jacintha M. ;

de Haan, Lolke .

CURRENT OPINION IN PHARMACOLOGY, 2012, 12 (05) :615-622

[13] Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers [J].

Cardillo, Thomas M. ;

Govindan, Serengulam V. ;

Sharkey, Robert M. ;

Trisal, Preeti ;

Arrojo, Roberto ;

Liu, Donglin ;

Rossi, Edmund A. ;

Chang, Chien-Hsing ;

Goldenberg, David M. .

BIOCONJUGATE CHEMISTRY, 2015, 26 (05) :919-931

[14] Antibody-drug conjugates for cancer [J].

Chau, Cindy H. ;

Steeg, Patricia S. ;

Figg, William D. .

LANCET, 2019, 394 (10200) :793-804

[15] Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer [J].

Cortes, J. ;

Kim, S. -B ;

Chung, W. -P ;

Im, S. -A ;

Park, Y. H. ;

Hegg, R. ;

Kim, M. H. ;

Tseng, L. -M ;

Petry, V ;

Chung, C. -F ;

Iwata, H. ;

Hamilton, E. ;

Curigliano, G. ;

Xu, B. ;

Huang, C. -S ;

Kim, J. H. ;

Chiu, J. W. Y. ;

Pedrini, J. L. ;

Lee, C. ;

Liu, Y. ;

Cathcart, J. ;

Bako, E. ;

Verma, S. ;

Hurvitz, S. A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (12) :1143-1154

[16] Targeting brain metastases in breast cancer [J].

Corti, Chiara ;

Antonarelli, Gabriele ;

Criscitiello, Carmen ;

Lin, Nancy U. ;

Carey, Lisa A. ;

Cortes, Javier ;

Poortmans, Philip ;

Curigliano, Giuseppe .

CANCER TREATMENT REVIEWS, 2022, 103

[17] Anti body-targeted chemotherapy with immunoconjugates of calicheamicin [J].

Damle, NK ;

Frost, P .

CURRENT OPINION IN PHARMACOLOGY, 2003, 3 (04) :386-390

[18] Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial [J].

Dieras, Veronique ;

Miles, David ;

Verma, Sunil ;

Pegram, Mark ;

Welslau, Manfred ;

Baselga, Jose ;

Krop, Ian E. ;

Blackwell, Kim ;

Hoersch, Silke ;

Xu, Jin ;

Green, Marjorie ;

Gianni, Luca .

LANCET ONCOLOGY, 2017, 18 (06) :732-742

[19] Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study [J].

Doi, Toshihiko ;

Shitara, Kohei ;

Naito, Yoichi ;

Shimomura, Akihiko ;

Fujiwara, Yasuhiro ;

Yonemori, Kan ;

Shimizu, Chikako ;

Shimoi, Tatsunori ;

Kuboki, Yasutoshi ;

Matsubara, Nobuaki ;

Kitano, Atsuko ;

Jikoh, Takahiro ;

Lee, Caleb ;

Fujisaki, Yoshihiko ;

Ogitani, Yusuke ;

Yver, Antoine ;

Tamura, Kenji .

LANCET ONCOLOGY, 2017, 18 (11) :1512-1522

[20] Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: Effects of linker technology on efficacy and toxicity [J].

Doronina, SO ;

Mendelsohn, BA ;

Bovee, TD ;

Cerveny, CG ;

Alley, SC ;

Meyer, DL ;

Oflazoglu, E ;

Toki, BE ;

Sanderson, RJ ;

Zabinski, RF ;

Wahl, AF ;

Senter, PD .

BIOCONJUGATE CHEMISTRY, 2006, 17 (01) :114-124

← 1 2 3 4 5 6 7 8 9 10 →